Global Newborn Screening LC-MS Reagent Kit Revenue Is Nearly 212 M USD
Monday, 05 Nov, 2018
Newborn screening is the practice of testing every newborn for certain harmful or potentially fatal disorder that isn’t otherwise apparent at birth. In the newborn screening, LC- MS/MS method is mainly applied to the detection of amino acids and acyl carnitines in blood.
Tandem mass spectrometry makes it possible to detect extremely low concentrations of compounds that can be used to indicate whether a baby is likely to have an inborn metabolic disorder.
In the last several years, global market of Newborn Screening LC-MS Reagent Kit developed rapidly, with an average growth rate of 8.7%. In 2017, global revenue of Newborn Screening LC-MS Reagent Kit is nearly 212 M USD; the actual Sales is about 39.8 million units.
The classification according to the material of Newborn Screening LC-MS Reagent Kit includes Non-derivatized Assay Solutions, Derivatized Assay Solutions, and the proportion of Non-derivatized Assay Solutions in 2017 is about 65.5%.
Newborn Screening LC-MS Reagent Kit is widely used to test Protein Metabolism, Fatty Acid Metabolism, Organic Acid Metabolism, the most proportion of Newborn Screening LC-MS Reagent Kit is used to test Protein Metabolism, and the proportion in 2017 is about 44.2%.
China is the largest sales place, with a sales market share nearly 21.8% in 2017. The demand for Newborn Screening LC-MS Reagent Kit in China is expected to witness growth owing to the increasing of newborn population.
Market competition is not intense. Perkinelmer is the leaders of the industry with 85% market share, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.